MediciNova, Inc. (MNOV)
MNOV Stock Price Chart
Explore MediciNova, Inc. interactive price chart. Choose custom timeframes to analyze MNOV price movements and trends.
MNOV Company Profile
Discover essential business fundamentals and corporate details for MediciNova, Inc. (MNOV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 2006
Employees
13.00
Website
https://www.medicinova.comCEO
Yuichi Iwaki
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MNOV Financial Timeline
Browse a chronological timeline of MediciNova, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.08.
Earnings released on 14 Aug 2025
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $134.60K .
Earnings released on 13 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.14 by +57.14%.
Earnings released on 19 Feb 2025
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 13 Nov 2024
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 8 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 9 May 2024
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%.
Earnings released on 15 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%, while revenue for the quarter reached -$999.77M .
Earnings released on 9 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.08 by +87.50%, while revenue for the quarter reached $1.00B .
Earnings released on 9 Aug 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 11 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 16 Feb 2023
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%.
Earnings released on 10 Nov 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 11 Aug 2022
EPS came in at -$0.08 matching the estimated -$0.08.
Earnings released on 12 May 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 16 Feb 2022
EPS came in at -$0.04 surpassing the estimated -$0.09 by +55.56%, while revenue for the quarter reached $4.03B .
Earnings released on 12 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $37.50K , missing expectations by -18.18%.
Earnings released on 12 Aug 2021
EPS came in at -$0.09 matching the estimated -$0.09.
Earnings released on 13 May 2021
EPS came in at -$0.00 surpassing the estimated -$0.08 by +95.06%, while revenue for the quarter reached $4.00M , missing expectations by -43.04%.
Earnings released on 18 Feb 2021
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%.
Earnings released on 26 Oct 2020
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%.
MNOV Stock Performance
Access detailed MNOV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.